The Effect of Vitamin D Supplementation on Hypothyroidism in the Randomized Controlled D-Health Trial

Thyroid. 2023 Nov;33(11):1302-1310. doi: 10.1089/thy.2023.0317. Epub 2023 Oct 5.

Abstract

Background: Hypothyroidism is common, and in iodine-sufficient areas, it is primarily caused by autoimmune destruction of the thyroid gland. Observational studies have consistently shown an inverse association between serum 25-hydroxyvitamin D concentration and autoimmune diseases; however, there is a lack of evidence from randomized controlled trials to support a benefit of vitamin D supplementation, particularly for autoimmune thyroid diseases. We, therefore, aimed to assess the effect of vitamin D supplementation on the incidence of hypothyroidism. Methods: We analyzed data from the D-Health Trial (n = 21,315), a randomized double-blind placebo-controlled trial of 60,000 international units per month of supplemental vitamin D3 among Australians aged 60 years and over. Hypothyroidism, a tertiary outcome of the D-Health Trial, was defined by treatment with levothyroxine, ascertained through linkage with the Australian Pharmaceutical Benefits Scheme. The outcome was time to first prescription of levothyroxine. We began follow-up at 12 months after randomization; people who had died or who had been dispensed levothyroxine during the first year were excluded. Flexible parametric survival models were used to assess the effect of vitamin D supplementation on hypothyroidism, overall and within strata defined by age, sex, body mass index, and predicted baseline vitamin D status. Results: We included 17,851 participants in the main analysis (vitamin D = 8939; placebo = 8912). During a median follow-up of 4.1 years (interquartile range 4.1-4.1), 293 participants developed hypothyroidism (vitamin D = 138 [1.5%]; placebo = 155 [1.7%]). Vitamin D supplementation did not significantly reduce the incidence of hypothyroidism (overall hazard ratio [HR] 0.89; 95% confidence interval [CI] 0.71-1.12). There was some suggestion of an effect in females (overall HR 0.78; CI 0.58-1.06) but not in males (overall HR 1.06; CI 0.74-1.50; p interaction 0.20). Conclusions: Vitamin D supplementation did not reduce the incidence of hypothyroidism overall; however, the possible beneficial effect observed in females warrants further investigation. Clinical Trial Registration: Australian New Zealand Clinical Trials Registry: ACTRN12613000743763.

Keywords: hypothyroidism; randomized controlled trial; vitamin D supplementation.

MeSH terms

  • Aged
  • Australia / epidemiology
  • Dietary Supplements / analysis
  • Double-Blind Method
  • Female
  • Humans
  • Hypothyroidism* / drug therapy
  • Hypothyroidism* / epidemiology
  • Hypothyroidism* / prevention & control
  • Male
  • Middle Aged
  • Pharmaceutical Preparations
  • Randomized Controlled Trials as Topic
  • Thyroxine*
  • Vitamin D / therapeutic use
  • Vitamins / therapeutic use

Substances

  • Thyroxine
  • Vitamin D
  • Vitamins
  • Pharmaceutical Preparations